6IO Stock Overview A medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Price History & Performance
Summary of share price highs, lows and changes for Inogen Historical stock prices Current Share Price US$8.10 52 Week High US$11.60 52 Week Low US$4.72 Beta 1.03 1 Month Change -8.99% 3 Month Change -14.74% 1 Year Change 54.29% 3 Year Change -71.68% 5 Year Change -87.34% Change since IPO -95.71%
Recent News & Updates
New minor risk - Shareholder dilution Nov 12
Third quarter 2024 earnings released: US$0.25 loss per share (vs US$1.97 loss in 3Q 2023) Nov 09
Inogen, Inc. Provides Revenue Guidance for the Full Year 2024 Nov 08
Inogen, Inc. to Report Q3, 2024 Results on Nov 07, 2024 Oct 17
Inogen Launches Rove 4 Portable Oxygen Concentrator, Delivering the Highest Oxygen Output in the Lightest Weight 4-Setting Poc Oct 09
New minor risk - Shareholder dilution Aug 09 See more updates
New minor risk - Shareholder dilution Nov 12
Third quarter 2024 earnings released: US$0.25 loss per share (vs US$1.97 loss in 3Q 2023) Nov 09
Inogen, Inc. Provides Revenue Guidance for the Full Year 2024 Nov 08
Inogen, Inc. to Report Q3, 2024 Results on Nov 07, 2024 Oct 17
Inogen Launches Rove 4 Portable Oxygen Concentrator, Delivering the Highest Oxygen Output in the Lightest Weight 4-Setting Poc Oct 09
New minor risk - Shareholder dilution Aug 09
New major risk - Share price stability Aug 07
Second quarter 2024 earnings released: US$0.24 loss per share (vs US$0.42 loss in 2Q 2023) Aug 07
Inogen, Inc. Provides Revenue Guidance for the Full Year 2024 Aug 07
Inogen, Inc. to Report Q2, 2024 Results on Aug 06, 2024 Jul 16
Inogen, Inc. Appoints Kevin P. Smith as General Counsel and Executive Vice President, Business Development, Effective July 22, 2024 Jul 04
Inogen, Inc. Announces Publication of Study Demonstrating the Association of Portable Oxygen Therapy with Decreased Survival and Increased Cost-Effectiveness Ratio Jun 05
Executive VP recently sold €79k worth of stock May 15
First quarter 2024 earnings released: US$0.62 loss per share (vs US$0.88 loss in 1Q 2023) May 08
Inogen, Inc. Provides Revenue Guidance for the Second Quarter of 2024 May 08
New minor risk - Shareholder dilution Apr 21
Inogen, Inc., Annual General Meeting, Jun 05, 2024 Apr 20
Inogen, Inc. to Report Q1, 2024 Results on May 07, 2024 Apr 11
Inogen, Inc. Provides Earnings Guidance for the First Quarter 2024 Feb 29
Full year 2023 earnings released: US$4.42 loss per share (vs US$3.67 loss in FY 2022) Feb 28
Inogen, Inc. to Report Q4, 2023 Results on Feb 27, 2024 Jan 31 Inogen, Inc. Announces CFO Changes, Effective March 4, 2024
Inogen, Inc. Appoints Grgoire Ramade to Serve as Chief Commercial Officer Jan 05
Inogen, Inc. Announces Separation Agreement with Nabil Shabshab Nov 29
Inogen, Inc. Announces Separation Agreement with Nabil Shabshab Nov 28 Inogen Announces CEO Changes
Third quarter 2023 earnings released: US$1.97 loss per share (vs US$0.41 loss in 3Q 2022) Nov 10
New minor risk - Market cap size Oct 29
Inogen, Inc. to Report Q3, 2023 Results on Nov 07, 2023 Oct 11 Inogen, Inc. Announces Executive Changes
Second quarter 2023 earnings released: US$0.42 loss per share (vs US$0.15 loss in 2Q 2022) Aug 08
Inogen, Inc. Announces the Introduction of the Rove 6(Tm) Portable Oxygen Concentrators in the United States Aug 08
Inogen, Inc. Announces Board Changes Aug 02 Inogen, Inc. to Report Q2, 2023 Results on Aug 07, 2023
Inogen, Inc. Reiterates Earnings Guidance for the Year 2023 May 07
First quarter 2023 earnings released: US$0.88 loss per share (vs US$0.63 loss in 1Q 2022) May 06
Full year 2022 earnings released: US$3.67 loss per share (vs US$0.28 loss in FY 2021) Feb 26
Inogen, Inc. Announces Bart Sanford to Step Down as Executive Vice President, Operations Effective on or Before March 1, 2023 Feb 11 Inogen, Inc. to Report Q4, 2022 Results on Feb 23, 2023
High number of new and inexperienced directors Nov 16
Third quarter 2022 earnings released: US$0.41 loss per share (vs US$0.54 profit in 3Q 2021) Nov 03
Inogen, Inc. Provides Revenue Guidance for the Fourth Quarter of 2022 Nov 03
Inogen, Inc. to Report Q3, 2022 Results on Nov 02, 2022 Oct 06
Second quarter 2022 earnings released: US$0.15 loss per share (vs US$0.23 profit in 2Q 2021) Aug 06
High number of new and inexperienced directors Aug 06
Inogen, Inc. to Report Q2, 2022 Results on Aug 04, 2022 Jul 09 Inogen, Inc.(NasdaqGS:INGN) dropped from Russell 2000 Growth-Defensive Index
Inogen, Inc. Names Agnes Lee as Senior Vice President of Investor Relations and Strategic Planning, Effective May 23, 2022 May 19 Inogen, Inc. Provides Earnings Guidance for the Second Quarter of 2022
High number of new and inexperienced directors Apr 27
Inogen, Inc., Annual General Meeting, Jun 08, 2022 Apr 22
Inogen, Inc. Announces Management Changes Apr 20
Inogen, Inc. to Report Q1, 2022 Results on May 05, 2022 Apr 15
High number of new and inexperienced directors Apr 02 Inogen, Inc. Executive Changes
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Feb 26
Loren McFarland Not to Stand for Re-Election as Director of Inogen, Inc Jan 30
Inogen, Inc. Provides Preliminary Unaudited Revenue Guidance for the Three-Month and Twelve-Month Periods Ended December 31, 2021 Jan 12
Third quarter 2021 earnings released: EPS US$0.54 (vs US$0.077 loss in 3Q 2020) Nov 07
Second quarter 2021 earnings released: EPS US$0.23 (vs US$0.12 in 2Q 2020) Aug 05 Inogen, Inc.(NasdaqGS:INGN) dropped from Russell 3000E Value Index
Inogen, Inc. Unable to Provide Guidance for the Full Year 2021 May 05
Inogen Announces Board Changes Mar 07
Inogen, Inc. Unables to Provide Guidance for the Full Year 2021 Feb 25
Inogen, Inc Announces Management Changes Feb 18
Independent Director has left the company Feb 17
Inogen, Inc. to Report Q4, 2020 Results on Feb 24, 2021 Feb 10
New 90-day high: €42.00 Feb 04
Inogen, Inc. Announces Change of Chief Executive Officers Jan 28
Inogen, Inc. Announces Board Changes Jan 26
Inogen, Inc. Unable to Provide Guidance for the Full Year 2020 or 2021 Nov 06
Inogen, Inc. to Report Q3, 2020 Results on Nov 04, 2020 Oct 15
New 90-day low - €22.80 Sep 10
New 90-day low - €24.80 Aug 25
First half earnings released Aug 06
Inogen, Inc. to Report Q2, 2020 Results on Aug 04, 2020 Jul 08 Shareholder Returns 6IO DE Medical Equipment DE Market 7D -10.5% -2.3% -1.4% 1Y 54.3% -6.9% 8.0%
See full shareholder returns
Return vs Market: 6IO exceeded the German Market which returned 8% over the past year.
Price Volatility Is 6IO's price volatile compared to industry and market? 6IO volatility 6IO Average Weekly Movement 6.4% Medical Equipment Industry Average Movement 6.7% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.9% 10% least volatile stocks in DE Market 2.5%
Stable Share Price: 6IO has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: 6IO's weekly volatility (6%) has been stable over the past year.
About the Company Inogen, Inc., a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The company offers Inogen One, a portable device that concentrate the air around the patient to provide a source of supplemental oxygen; Inogen At Home stationary oxygen concentrators; Simeox airway clearance; batteries; and related accessories.
Show more Inogen, Inc. Fundamentals Summary How do Inogen's earnings and revenue compare to its market cap? 6IO fundamental statistics Market cap €195.27m Earnings (TTM ) -€50.82m Revenue (TTM ) €319.75m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 6IO income statement (TTM ) Revenue US$331.52m Cost of Revenue US$184.91m Gross Profit US$146.61m Other Expenses US$199.30m Earnings -US$52.69m
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/19 00:02 End of Day Share Price 2024/12/19 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Inogen, Inc. is covered by 9 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Robert Marcus J.P. Morgan Matthew Mishan KeyBanc Capital Markets Inc. Jeffrey Cohen Ladenburg Thalmann & Company
Show 6 more analysts 
